Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | GLS | O94925 | 4/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32685349 | 0.79 | TRPV1 (0.39) | TRPV1GLSSLC6A7 | |
| SCHEMBL30294914 | 0.76 | CHRNA7 (0.55) | HTR3A | |
| SCHEMBL3566046 | 0.75 | CHRNB2 (0.36) | HTR3A | |
| SCHEMBL3574996 | 0.75 | CHRNB2 (0.56) | — | |
| SCHEMBL31014220 | 0.75 | HRH3 (0.39) | GLS | |
| SCHEMBL3583955 | 0.74 | HTR3E (0.54) | HTR3A | |
| SCHEMBL3570950 | 0.74 | GRIN2B (0.42) | HTR3A | |
| SCHEMBL2676639 | 0.74 | CHRNA7 (0.64) | HTR3A | |
| SCHEMBL16061561 | 0.73 | DPP4 (0.45) | TRPV1GLSSLC6A7RIPK1 | |
| SCHEMBL15378530 | 0.73 | DPP4 (0.40) | TRPV1GLSHTR3ASLC6A7RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687523-B2 | 3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists | NEUROSEARCH A/S (DK) | 2010-03-30 | — | — | US | claimed |
| US-20090005388-A1 | 3-Heteroaryl-3,9-Diazabicyclo[3.3.1]Nonane Derivatives as Nicotinic Acetylcholine Receptor Agonists | GLORIANA THERAPEUTICS, INC. | 2009-01-01 | — | — | US | claimed |
| EP-1987031-A1 | 3-HETEROARYL- 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NeuroSearch A/S (DK) | 2008-11-05 | — | — | EP | claimed |
| WO-2007090888-A1 | 3-HETEROARYL- 3,9-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NEUROSEARCH A/S (DK) | 2007-08-16 | — | — | WO | claimed |
| US-7687523-B2 | 3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists | NEUROSEARCH A/S (DK) | 2010-03-30 | — | — | US | disclosed |
| US-20090005388-A1 | 3-Heteroaryl-3,9-Diazabicyclo[3.3.1]Nonane Derivatives as Nicotinic Acetylcholine Receptor Agonists | GLORIANA THERAPEUTICS, INC. | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005388-A1 | 3-Heteroaryl-3,9-Diazabicyclo[3.3.1]Nonane Derivatives as Nicotinic Acetylcholine Receptor Agonists | CHRNA3, CHRNA10, CHRNB3 | TRPV1 125/4885GLS 2343/4885PDE10A 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.